<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Oldgren, Jonas</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Data from RE-DEEM and RE-LY</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-23</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses results from the Phase 2 dose-ranging RE-DEEM Trial, as well as results of a post hoc analysis of data from the RE-LY Trial.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>